Dendritic cell vaccination as a treatment modality for mesothelioma

Expert Review of Respiratory Medicine

Volumn 4, Issue 3, 2010, Pages 311-314

  Gregoire, Marc ^a  

^a Unit 892   (France)

Author keywords

Dendritic cells; Immunotherapy; Malignant mesothelioma; Vaccine

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; CAT 5001; CISPLATIN; CRS 207; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DOXORUBICIN; MORAB 009; PARACETAMOL; PEMETREXED; RALTITREXED; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CYTOTOXICITY; DRUG FEVER; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FLU LIKE SYNDROME; HUMAN; LOW DRUG DOSE; MALIGNANT MESOTHELIOMA; NOTE; SKIN MANIFESTATION; UNSPECIFIED SIDE EFFECT;

EID: 77953283494     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.10.33     Document Type: Note

References (19)

1. Steele JP, Klabatsa A, Fennell DA et al. Prognostic factors in mesothelioma. Lung Cancer 49(Suppl. 1), S49-S52 (2005).
2. Boutin C, Schlesser M, Frenay C, Astoul P. Malignant pleural mesothelioma. Eur. Respir. J. 12(4), 972-981 (1998).
3. Hegmans JP, Veltman JD, Lambers ME et al. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am. J. Respir. Crit. Care Med. DOI: 10.1164/ rccm.200909-1465OC (2010) (Epub ahead of print).
4. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21(14), 2636-2644 (2003).
5. Gregoire M. What's the place of immunotherapy in malignant mesothelioma treatments? Cell. Adh. Migr. 4(1), 153-161 (2010).
6. Gregoire M, Ligeza-Poisson C, Juge-Morineau N, Spisek R. Anti-cancer therapy using dendritic cells and apoptotic tumour cells: pre-clinical data in human mesothelioma and acute myeloid leukaemia. Vaccine 21(7-8), 791-794 (2003).
7. Hegmans JP, Hemmes A, Aerts JG, Hoogsteden HC, Lambrecht BN. Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells. Am. J. Respir. Crit. Care Med. 171(10), 1168-1177 (2005).
8. Vulink A, Radford KJ, Melief C, Hart DN. Dendritic cells in cancer immunotherapy. Adv. Cancer Res. 99, 363-407 (2008).
9. Powell A, Creaney J, Broomfield S, Van Bruggen I, Robinson B. Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma. Lung Cancer 52(2), 189-197 (2006).
10. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 5(4), 296-306 (2005).
11. Simon T, Fonteneau J-F, Grégoire M. Dendritic cell preparation for immunotherapeutic interventions. Immunotherapy 1(2), 289-302 (2009).
12. Hegmans JP, Hemmes A, Hammad H, Boon L, Hoogsteden HC, Lambrecht BN. Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur. Respir. J. 27(6), 1086-1095 (2006).
13. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol. 21(2), 233-240 (2009).
14. Scherpereel A, Astoul P, Baas P et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur. Respir. J. 35(3), 479-495 (2010).
15. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8(1), 59-73 (2008).
16. McCoy MJ, Nowak AK, Lake RA. Chemoimmunotherapy: an emerging strategy for the treatment of malignant mesothelioma. Tissue Antigens 74(1), 1-10 (2009).
17. Vandermeers F, Hubert P, Delvenne P et al. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin. Cancer Res. 15(8), 2818-2828 (2009).
18. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur. J. Cancer 44(1), 46-53 (2008).
19. Gauvrit A, Brandler S, Sapede-Peroz C, Boisgerault N, Tangy F, Gregoire M. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. Cancer Res. 68(12), 4882-4892 (2008).